Functional genomics of lung cancer. Identification of new markers and molecular targets for the treatment of lung cancer using omics technologies (transcriptomics, proteomics, metabolomics). Study of the mechanisms of innate and acquired resistance to tyrosine kinase inhibitors based on the epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. Regulation of tumour metabolism by oncogenes and suppressor genes in lung cancer.
Identification of new markers and molecular targets for the treatment of pulmonary fibrosis. Identification of molecular determinants of fibroblast-myofibroblast transition using omics technologies. Role of inflammation and stroma in the tumour microenvironment and lung cancer progression.
Development of effective therapeutic approaches that enable both therapeutic avoidance and eradication of the disease before metastasis.
We want to cross a strain of tumour-prone mice with our FN-syn mice and analyse the influence of this mutation on tumour development, migration and metastasis formation of tumour cells.
